Lung cancer drug could improve survival rates for bladder cancer patients undergoing chemotherapy - EurekAlert

Researchers found that adding nintedanib - a targeted cancer growth inhibitor currently used to treat non-small cell lung cancer - to chemotherapy, could significantly improve overall survival rate for bladder cancer patients at one, two and five years.

**Strictly under embargo until 23:30 (BST) Monday 11 April 2022**

• Phase two randomised placebo controlled trial (NEOBLADE) showed giving patients nintedanib, as well as chemotherapy before s… [+4688 chars]
  full article...